Isolation-induced aggression in mice: effects of 5-hydroxytryptamine uptake inhibitors and involvement of postsynaptic 5-HT1A receptors.

C. Sánchez,J. Hyttel

DOI: https://doi.org/10.1016/0014-2999(94)00470-6

IF: 5.195

1994-11-03

European Journal of Pharmacology

Abstract:

What problem does this paper attempt to address?

Research Progress of HIV-1 Integrase and Its Inhibitors

Shen Xuebin,Ye Jian,Yang Lili,Chen Huan,Lou Yijia

DOI: https://doi.org/10.11844/cjcb.2013.10.0152

2013-01-01

Abstract:After reverse transcription, the integrase enzyme catalyzes incorporation of HIV-1(human immunodeficiency virus type 1) cDNA into the host cell genome, which is called integration. Since integration is vital to viral replication, the inhibition of integrase will definitely show a promising access to anti-HIV chemotherapy.This paper reviews the structure and function of integrase, as well as the latest progress of researches focusing on the inhibitors of integrase.
Latest advances in the efficacy, tolerability, and monotherapy of integrase inhibitors

Qi Tang,Hongzhou Lu

DOI: https://doi.org/10.5582/bst.2017.01194

2017-01-01

BioScience Trends

Abstract:More than 30 drugs for antiretroviral therapy (ART), including integrase inhibitors (INIs), have been approved by the U.S. Food and Drug Administration (FDA) as of 2017. Integrase is the third essential enzyme in the cycle of human immunodeficiency virus (HIV) replication. INIs can effectively inhibit the replication of HIV and HIV is less prone to develop resistance to INIs clinically. Previous studies based on 7 phase III clinic trials indicate that INIs have satisfactory efficacy and tolerability in patients infected with HIV. The latest advances in INIs indicate that: i) dolutegravir (DTG)-based regimens are more efficacious, tolerable, and safer forms of first-second-and third-Line ART; ii) current studies have indicated that DTG monotherapy fails both virologically and clinically; and iii) whether the most cost-effective treatment for DTG is to replace efavirenz (EFV) as a first-line ART, to replace protease inhibitors (PIs) in second-line ART, or to replace both as a monotherapy is unclear. Given these circumstances, further study of INIs in terms of drug interactions, dose reduction, drug convenience, and drug costs is warranted.
Meta-analysis and Systematic Review of the Efficacy and Resistance for Human Immunodeficiency Virus Type 1 Integrase Strand Transfer Inhibitors.

Li-Li Yang,Qi Li,Li-Bo Zhou,Shu-Qing Chen

DOI: https://doi.org/10.1016/j.ijantimicag.2019.08.008

IF: 15.441

2019-01-01

International Journal of Antimicrobial Agents

Abstract:Integrase strand transfer inhibitors (INSTIs) are the most recent class of antiretroviral drugs with potent and durable antiviral activity used to treat human immunodeficiency virus type 1 (HIV-1) infection. However, development of drug resistance increases the risk of treatment failure, disease progression and mortality. A better understanding of drug efficacy and resistance against INSTIs is crucial for their efficient use and the development of new antiretrovirals. A meta-analysis of studies reporting efficacy and resistance data on INSTI use in HIV-infected patients was performed. Odds ratios (ORs) of efficacy outcome data favouring INSTI use in different clinical settings demonstrated that INSTIs have higher efficacy compared with drugs of other classes. For combination antiretroviral therapy-naïve patients and virologically-suppressed patients who switched to INSTI-based therapy, the OR was 1.484 (95% CI 1.229-1.790) and 1.341 (95% CI 0.913-1.971), respectively. ORs of resistance data indicated decreased treatment-emergent resistance development to dolutegravir (DTG) upon virological failure than to non-INSTIs (OR = 0.081, 95% CI 0.004-1.849), whereas the opposite was observed for raltegravir (RAL) (OR = 3.137, 95% CI 1.827-5.385) and elvitegravir (EVG) (OR = 1.886, 95% CI 0.569-6.252). Pooled analysis of resistance data indicated that development of resistance to DTG and bictegravir was rare, whereas EVG and RAL had low genetic barriers to resistance and the intensive cross-resistance between them limits INSTI efficiency. Efficient means of monitoring the emergence of resistance to INSTIs and the development of drugs with high genetic barriers are clear paths for future research.
Clinical Significance and Management of Low-Level HIV Viremia in the Era of Integrase Strand Transfer Inhibitors

Jinchuan Shi,Gaoxiang Ying,Rongrong Zheng,Zhongdong Zhang

DOI: https://doi.org/10.1111/hiv.13585

2024-01-01

HIV Medicine

Abstract:BACKGROUND:People living with HIV (PLWH) and receiving antiretroviral therapy (ART) have a goal of achieving and maintaining viral suppression; however, the existence of PLWH that show events of low-level viremia (LLV) between 50 and 1000 copies/mL and with different virological consequences have been observed. Moreover, some reports indicate that LLV status can lead to residual immune activation and inflammation, leading to a higher occurrence of non-AIDS-defining events (nADEs) and other adverse clinical outcomes. Until now, however, published data have shown controversial results that hinder understanding of this phenomenon's actual cause(s) and origin(s). Integrase strand transfer inhibitors (INSTIs)-based therapies could lead to lower LLV over time and, therefore, more effective virological control. OBJECTIVES:This review aims to assess recent findings to provide a view of the clinical significance and management of low-level HIV viremia in the era of INSTIs.
Integrase Inhibitors Partially Restore Bacterial Translocation, Inflammation and Gut Permeability Induced by HIV Infection: Impact on Gut Microbiota

Pablo Villoslada-Blanco,Patricia Pérez-Matute,María Íñiguez,Emma Recio-Fernández,Pilar Blanco-Navarrete,Luis Metola,Valvanera Ibarra,Jorge Alba,María de Toro,José A. Oteo

DOI: https://doi.org/10.1007/s40121-022-00654-4

2022-07-30

Infectious Diseases and Therapy

Abstract:Human immunodeficiency virus (HIV) infection can be considered a chronic disease thanks to the extended use of antiretroviral treatment (ART). In this context, low-grade chronic inflammation related to gut microbiota (GM) dysbiosis and bacterial translocation (BT) among other factors has been observed despite the use of ART. In addition, different ART regimens have demonstrated differential impacts on GM. However, the role of novel integrase strand transfer inhibitors (INSTIs) has not been investigated yet. The aim of this study was to analyse the effects of INSTIs in first-line of treatment on markers of BT, inflammation, cardiovascular risk, gut permeability and GM composition and derived short-chain fatty acids.

infectious diseases
A mini-review on integrase inhibitors: The cornerstone of next-generation HIV treatment

Fathi Shalbi,Ahmed R. Ali

DOI: https://doi.org/10.1016/j.ejmech.2024.116900

IF: 7.088

2024-09-29

European Journal of Medicinal Chemistry

Abstract:Integrase inhibitors represent one of the most remarkable and effective advances in the treatment of HIV-1 infection. Their lack of human cellular equivalence has established integrase as a unique and ideal target for HIV-1 treatment. Over the last two decades, a variety of drugs and small molecule inhibitors have been developed to control or treat HIV infection. Many of these FDA-approved drugs are considered first-line options for AIDS patients. Unfortunately, resistance to these drugs has dictated the development of novel and more efficacious antiretroviral drugs. In this review article, we illustrate the key classes of antiretroviral integrase inhibitors available. We provide a comprehensive analysis of recent advancements in the development of integrase inhibitors, focusing on novel compounds and their distinct mechanisms of action. Our literature review highlights emerging allosteric integrase inhibitors that offer improved efficacy, resistance profiles, and pharmacokinetics. By integrating these recent advancements and clinical insights, this review aims to provide a thorough and updated understanding of integrase inhibitors, emphasizing their evolving role in HIV treatment.

chemistry, medicinal
Progress in Research on HIV-1 Integrase and Its Inhibitors

LI Fang-qiong,DING Qian,ZHAN Jin-biao

DOI: https://doi.org/10.3969/j.issn.1671-8135.2008.01.015

2008-01-01

Abstract:HIV-1 integrase enzyme is a 32kDa protein encoded by HIV pol gene. It is responsible for integration of viral cDNA into host chromosomal DNA, which is indispensable for HIV replication.Since there was no functional equivalent for this enzyme in human cells, inhibition of integrase will bring little side effect to human body. Thus HIV integrase has become an attractive and rational target for therapy of AIDS after reverse transcriptase and protease.The Recent research on HIV-1integrase structure,inhibitors and new therapeutic method target at HIV integrase was reviewed.
The successes and failures of HIV drug discovery

Chie Hashimoto,Tomohiro Tanaka,Tetsuo Narumi,Wataru Nomura,Hirokazu Tamamura

DOI: https://doi.org/10.1517/17460441.2011.611129

Abstract:Introduction: To date, several anti-human immunodeficiency virus (HIV) drugs, including reverse transcriptase inhibitors and protease inhibitors, have been developed and used clinically for the treatment of patients infected with HIV. Recently, novel drugs have been discovered which have different mechanisms of action from those of the above inhibitors, including entry inhibitors and integrase (IN) inhibitors; the clinical use of three of these inhibitors has been approved. Other inhibitors are still in development. Areas covered: This review article summarizes the history of the development of anti-HIV drugs and also focuses on successes in the development of these entry and IN inhibitors, along with looking at exploratory approaches for the development of other inhibitors. Expert opinion: Currently used highly active antiretroviral therapy can be subject to a loss of efficacy, due to the emergence of multi-drug resistant (MDR) strains; a change of regimens of the drug combination is required to combat this, along with careful monitoring of the virus and CD4 in the blood, by methods such as cellular tropism testing. In such a situation, entry inhibitors such as CCR5/CXCR4 antagonists, CD4 mimics, fusion inhibitors and IN inhibitors might be optional agents for an expansion of the drug repertoire available to patients at all stages of HIV infection.
Current state-of-the-art in preclinical and clinical development of novel non-nucleoside HIV-1 reverse transcriptase inhibitors

Romano Silvestri,Giovanni Maga

DOI: https://doi.org/10.1517/13543776.16.7.939

2006-06-21

Expert Opinion on Therapeutic Patents

Abstract:In spite of the tremendous advance in our understanding of the HIV-1 life cycle and of the molecular mechanisms underlying its pathogenesis, it is still not possible to fully control the HIV-1 infection for long periods of time, not to mention eradicate it. However, as it is still unclear whether an effective vaccine could be developed in a short time, therapeutic approaches based on the combination of different potent antiviral drugs are now thought to be the best option for the control of HIV-1 infection in patients. For this reason, development of novel molecules that are safer, more potent and less sensitive to drug resistance than available drugs is mandatory. Among the currently exploited anti-HIV drugs, non-nucleoside reverse transcriptase inhibitors play a major role. This review will summarise the most recent advances and evolutionary trends for this class of anti-HIV drugs.

pharmacology & pharmacy,chemistry, medicinal
HIV Pol: does it offer therapeutic targets for HIV?

Camilla Muccini,Antonella Castagna

DOI: https://doi.org/10.1080/14728222.2024.2351510

IF: 6.797

2024-05-10

Expert Opinion on Therapeutic Targets

Abstract:KEYWORDS: One of the greatest challenges in the management of HIV infection is the search for new treatment strategies, including those aimed at achieving a functional or sterilizing cure. Although antiretroviral therapy (ART) has dramatically improved the survival and quality of life of people living with HIV (PLWH) over the years, treatment interruption leads to viral rebound; to date, no study has proven to be effective in achieving viral eradication [ Citation 1 , Citation 2 ]. However, increasing knowledge of the HIV genome is enabling the exploration of innovative potential therapeutic approaches.

pharmacology & pharmacy
Advances in the development of HIV integrase strand transfer inhibitors.

Yue Wang,Shuang-Xi Gu,Qiuqin He,Renhua Fan

DOI: https://doi.org/10.1016/j.ejmech.2021.113787

IF: 7.088

2021-01-01

European Journal of Medicinal Chemistry

Abstract:HIV-1 integrase (IN) is a key enzyme in viral replication that catalyzes the covalent integration of viral cDNA into the host genome. Currently, five HIV-1 IN strand transfer inhibitors (INSTIs) are approved for clinical use. These drugs represent an important addition to the armamentarium for antiretroviral therapy. This review briefly illustrates the development history of INSTIs. The characteristics of the currently approved INSTIs, as well as their future perspectives, are critically discussed.
Recent Advances in Computer-aided Antiviral Drug Design Targeting HIV-1 Integrase and Reverse Transcriptase Associated Ribonuclease H

Fengyuan Yang,Jingyi Yang,Zhao Zhang,Gao Tu,Xiaojun Yao,Weiwei Xue,Feng Zhu

DOI: https://doi.org/10.2174/0929867328666210708090123

IF: 4.74

2022-01-01

Current Medicinal Chemistry

Abstract:Acquired immunodeficiency syndrome (AIDS) has been a chronic, life-threatening disease for a long time. Though, a broad range of antiretroviral drug regimens is applicable for the successful suppression of virus replication in human immunodeficiency virus type 1 (HIV-1) infected people. The mutation-induced drug resistance problems during the treatment of AIDS forced people to continuously look for new antiviral agents. HIV-1 integrase (IN) and reverse transcriptase associated ribonuclease (RT-RNase H), two pivotal enzymes in HIV-1 replication progress, have gained popularity as druggable targets for designing novel HIV-1 antiviral drugs. During the development of HIV-1 IN and/or RT-RNase H inhibitors, computer-aided drug design (CADD), including homology modeling, pharmacophore, docking, molecular dynamics (MD) simulation and binding free energy calculation, represent a significant tool to accelerate the discovery of new drug candidates and reduce costs in antiviral drug development. In this review, we summarized the recent advances in the design of single-and dual-target inhibitors against HIV-1 IN or/and RT-RNase H as well as the prediction of mutation-induced drug resistance based on computational methods. We highlighted the results of the reported literatures and proposed some perspectives on the design of novel and more effective antiviral drugs in the future.
Pharmacological advances in anti‐retroviral therapy for human immunodeficiency virus‐1 infection: A comprehensive review

Nursyuhada Azzman,Muhammad Shoaib Ali Gill,Sharifah Syed Hassan,Frauke Christ,Zeger Debyser,Wan Ahmad Syazani Mohamed,Nafees Ahemad

DOI: https://doi.org/10.1002/rmv.2529

2024-03-25

Reviews in Medical Virology

Abstract:The discovery of anti‐retroviral (ARV) drugs over the past 36 years has introduced various classes, including nucleoside/nucleotide reverse transcriptase inhibitors, non‐nucleoside reverse transcriptase inhibitors, protease inhibitor, fusion, and integrase strand transfer inhibitors inhibitors. The introduction of combined highly active anti‐retroviral therapies in 1996 was later proven to combat further ARV drug resistance along with enhancing human immunodeficiency virus (HIV) suppression. As though the development of ARV therapies was continuously expanding, the variation of action caused by ARV drugs, along with its current updates, was not comprehensively discussed, particularly for HIV‐1 infection. Thus, a range of HIV‐1 ARV medications is covered in this review, including new developments in ARV therapy based on the drug's mechanism of action, the challenges related to HIV‐1, and the need for combination therapy. Optimistically, this article will consolidate the overall updates of HIV‐1 ARV treatments and conclude the significance of HIV‐1‐related pharmacotherapy research to combat the global threat of HIV infection.

virology
Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients

Matthew Weichseldorfer,Marvin Reitz,Olga S. Latinovic

DOI: https://doi.org/10.3390/pharmaceutics13111798

IF: 6.525

2021-10-27

Pharmaceutics

Abstract:Combined antiretroviral therapy (cART) is treatment with a combination of several antiretroviral drugs that block multiple stages in the virus replication cycle. An estimated 60% of the 38 million HIV-1 patients globally receive some form of cART. The benefits of cART for controlling HIV-1 replication, transmission, and infection rates have led to its universal recommendation. Implementation has caused a substantial reduction in morbidity and mortality of persons living with HIV-1/AIDS (PLWHA). More specifically, standard cART has provided controlled, undetectable levels of viremia, high treatment efficacy, reduction in pill burden, and an improved lifestyle in HIV-1 patients overall. However, HIV-1 patients living with AIDS (HPLA) generally show high viral loads upon cART interruption. Latently infected resting CD4+ T cells remain a major barrier to curing infected patients on long-term cART. There is a critical need for more effective compounds and therapies that not only potently reactivate latently infected cells, but also lead to the death of these reactivated cells. Efforts are ongoing to better control ongoing viral propagation, including the identification of appropriate animal models that best mimic HIV-1 pathogenesis, before proceeding with clinical trials. Limited toxicity profiles, improved drug penetration to certain tissues, and extended-release formulations are needed to cover gaps in existing HIV-1 treatment options. This review will cover past, current, and new cART strategies recently approved or in ongoing development.

pharmacology & pharmacy
Strategies for Inhibiting Function of HIV-1 Accessory Proteins: A Necessary Route to AIDS Therapy?

S N Richter,I Frasson,G Palù,S. Richter,I. Frasson,G. Palu

DOI: https://doi.org/10.2174/092986709787002646

IF: 4.74

2009-01-01

Current Medicinal Chemistry

Abstract:The Human Immunodeficiency Virus (HIV) genome encodes three major structural proteins common to all retroviruses (Gag, Pol and Env), two regulatory proteins (Tat and Rev) that are essential for viral replication, and four accessory proteins (Nef, Vif, Vpu, Vpr). While accessory proteins were initially reported to be unnecessary for viral growth, their importance as virulence factors is now being more and more appreciated: they can dramatically alter the course and severity of viral infection, replication and disease progression. None of the HIV accessory proteins display enzymatic activity: they rather act altering cellular pathways via multiple protein-protein interactions with a number of host cell factors. All currently approved anti-HIV drugs target pol and env encoded proteins. Therefore, widening the molecular targets of HIV therapy by additionally targeting accessory proteins may expand treatment options, resulting in high impact effective new therapy. In this review we present the state of the art of compounds that target HIV accessory proteins. Most of the research has focused on the inhibition of specific accessory proteins/host cell partner interactions. Promising compounds have been found within different classes of molecules: small natural and synthetic molecules, peptides and proteins, oligonucleotides, in particular those used as RNA interference (RNAi) tools. With the assortment of compounds available, especially against Nef and Vif functions, the demonstration of the clinical efficacy of the new anti-HIV-1 drugs targeting accessory proteins is next challenge.

pharmacology & pharmacy,biochemistry & molecular biology,chemistry, medicinal
Advanced Therapies for Human Immunodeficiency Virus

Daniel Josef Lindegger

DOI: https://doi.org/10.3390/medsci12030033

2024-07-18

Abstract:Human Immunodeficiency Virus (HIV) remains a significant global health challenge with approximately 38 million people currently having the virus worldwide. Despite advances in treatment development, the virus persists in the human population and still leads to new infections. The virus has a powerful ability to mutate and hide from the human immune system in reservoirs of the body. Current standard treatment with antiretroviral therapy effectively controls viral replication but requires lifelong adherence and does not eradicate the virus. This review explores the potential of Advanced Therapy Medicinal Products as novel therapeutic approaches to HIV, including cell therapy, immunisation strategies and gene therapy. Cell therapy, particularly chimeric antigen receptor T cell therapy, shows promise in preclinical studies for targeting and eliminating HIV-infected cells. Immunisation therapies, such as broadly neutralising antibodies are being investigated to control viral replication and reduce reservoirs. Despite setbacks in recent trials, vaccines remain a promising avenue for HIV therapy development. Gene therapy using technologies like CRISPR/Cas9 aims to modify cells to resist HIV infection or eliminate infected cells. Challenges such as off-target effects, delivery efficiency and ethical considerations persist in gene therapy for HIV. Future directions require further research to assess the safety and efficacy of emerging therapies in clinical trials. Combined approaches may be necessary to achieve complete elimination of the HIV reservoir. Overall, advanced therapies offer new hope for advancing HIV treatment and moving closer to a cure.
Blocking Viral Entry: a Complementary Strategy for HIV Therapy

Shibo Jiang,Pamela Siddiqui,Shuwen Liu

DOI: https://doi.org/10.1016/j.ddstr.2004.10.008

2004-01-01

Drug Discovery Today Therapeutic Strategies

Abstract:Applications of current antiretroviral drugs, including reverse transcriptase and protease inhibitors, have significantly increased life expectancy for HIV-infected individuals. However, increasing numbers of HIV-infected patients fail to respond to these drugs owing to emergence of drug resistance and adverse effects. Much progress has been made in recent years in development of novel anti-HIV drugs to block HIV entry into target cells. These HIV entry inhibitors can be used as a complementary strategy for HIV therapy.
Recent discoveries in HIV-1 reverse transcriptase inhibitors

Shuang-Xi Gu,Yuan-Yuan Zhu,Chao Wang,Hai-Feng Wang,Gen-Yan Liu,Shuang Cao,Lu Huang

DOI: https://doi.org/10.1016/j.coph.2020.09.017

IF: 4.768

2020-10-01

Current Opinion in Pharmacology

Abstract:HIV-1 reverse transcriptase inhibitors (RTIs) are indispensable components of highly active antiretroviral therapy (HAART), which has achieved great success in controlling AIDS epidemic in reducing drastically the morbidity and mortality of HIV-infected patients. RTIs are divided into two categories, nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs). In this review, the recent discoveries in NRTIs and NNRTIs, including approved anti-HIV drugs and noteworthy drug candidates in different development stages, are summarized, and their future direction is prospected.

pharmacology & pharmacy
Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: An update

Lu Sun,Peng Nie,Li Luan,Piet Herdewijn,Ya-Tao Wang

DOI: https://doi.org/10.1016/j.ejmech.2023.115847

2023-12-05

Abstract:Application of chemotherapeutic agents to inhibit the HIV replication process has brought about a significant metamorphosis in the landscape of AIDS. Substantial declines in morbidity and mortality rates have been attained, accompanied by notable decreases in healthcare resource utilization. However, treatment modalities do not uniformly inhibit HIV replication in every patient, while the emergence of drug-resistant viral strains poses a substantial obstacle to subsequent therapeutic interventions. Furthermore, chronic administration of therapy may lead to the manifestation of toxicities. These challenges necessitate the exploration of novel pharmacological agents and innovative therapeutic approaches aimed at effectively managing the persistent viral replication characteristic of chronic infection. This review examines the role of clinically approved small-molecule drugs in the treatment of HIV/AIDS, which provides an in-depth analysis of the major classes of small-molecule drugs, including nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors, entry inhibitors, and pharmacokinetic enhancers. The review mainly discusses the application, synthetic routes, and mechanisms of action of small-molecule drugs employed in the treatment of HIV, as well as their use in combination with antiretroviral therapy, presenting viewpoints on forthcoming avenues in the development of novel anti-HIV drugs.
Small-molecule Inhibitors of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Function: Challenges and Recent Developments

Valentina Noemi Madia,Antonella Messore,Alessandro De Leo,Valeria Tudino,Ivano Pindinello,Francesco Saccoliti,Daniela De Vita,Luigi Scipione,Roberta Costi,Roberto Di Santo

DOI: https://doi.org/10.2174/0929867328666210322164557

Abstract:Multiple combinations of antiretroviral drugs have remarkably improved the treatment of HIV-1 infection. However, life-long treatments and drug resistance are still an open issue that requires continuous efforts for the identification of novel antiviral drugs. Background: The reverse transcriptase-associated ribonuclease H (RNase H) hydrolyzes the HIV genome to allow synthesizing viral DNA. Currently, no RNase H inhibitors (RHIs) have reached the clinical phase. Therefore, RNase H can be defined as an attractive target for drug design. Objective: Despite the wealth of information available for RNase H domain, the development of RHIs with high specificity and low cellular toxicity has been disappointing. However, it is now becoming increasingly evident that reverse transcriptase is a highly versatile enzyme, undergoing major structural alterations to complete its catalysis, and that exists a close spatial and temporal interplay between reverse transcriptase polymerase and RNase H domains. This review sums up the present challenges in targeting RNase H encompassing the challenges in selectively inhibiting RNase H vs polymerase and/or HIV-1 integrase and the weak antiviral activity of active site inhibitors, probably for a substrate barrier that impedes small molecules to reach the targeted site. Moreover, the focus is given on the most recent progress in the field of medicinal chemistry that has led to the identification of several small molecules as RHIs in the last few years. Conclusion: RHIs could be a new class of drugs with a novel mechanism of action highly precious for the treatment of resistant HIV strains.

Isolation-induced aggression in mice: effects of 5-hydroxytryptamine uptake inhibitors and involvement of postsynaptic 5-HT1A receptors.

Research Progress of HIV-1 Integrase and Its Inhibitors

Latest advances in the efficacy, tolerability, and monotherapy of integrase inhibitors

Meta-analysis and Systematic Review of the Efficacy and Resistance for Human Immunodeficiency Virus Type 1 Integrase Strand Transfer Inhibitors.

Clinical Significance and Management of Low-Level HIV Viremia in the Era of Integrase Strand Transfer Inhibitors

Integrase Inhibitors Partially Restore Bacterial Translocation, Inflammation and Gut Permeability Induced by HIV Infection: Impact on Gut Microbiota

A mini-review on integrase inhibitors: The cornerstone of next-generation HIV treatment

Progress in Research on HIV-1 Integrase and Its Inhibitors

The successes and failures of HIV drug discovery

Current state-of-the-art in preclinical and clinical development of novel non-nucleoside HIV-1 reverse transcriptase inhibitors

HIV Pol: does it offer therapeutic targets for HIV?

Advances in the development of HIV integrase strand transfer inhibitors.

Recent Advances in Computer-aided Antiviral Drug Design Targeting HIV-1 Integrase and Reverse Transcriptase Associated Ribonuclease H

Pharmacological advances in anti‐retroviral therapy for human immunodeficiency virus‐1 infection: A comprehensive review

Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients

Strategies for Inhibiting Function of HIV-1 Accessory Proteins: A Necessary Route to AIDS Therapy?

Advanced Therapies for Human Immunodeficiency Virus

Blocking Viral Entry: a Complementary Strategy for HIV Therapy

Recent discoveries in HIV-1 reverse transcriptase inhibitors

Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: An update

Small-molecule Inhibitors of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Function: Challenges and Recent Developments